Disclaimer: AlphaGalileo is not responsible for the accuracy of news releases posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.
Halia plans to advance HT-6184 into a Phase 2 clinical trial for obesity later this year. This trial will evaluate the safety, tolerability, and efficacy of HT-6184 in combination with semaglutide for ...